Table 3. Overall Survival-Multivariate Analysis (adjusted for NLR ≥ 2.3, ECOG-PS ≥ 1, dermatological adverse events, hyperbilirrubinemia, hypertension, presence of vascular invasion, clinical ascites and previous TACE).

Variable	P	HR (95% CI)
NLR ≥ 2.3	0.019	1.72 (1.09–2.71)
ECOG-PS ≥ 1	0.008	1.97 (1.19–3.26)
Dermatological adverse events	0.019	0.59 (0.38–0.92)
Hyperbilirrubinemia (≥ 2 mg/dl)	< 0.001	3.42 (1.87–6.25)